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Intravenous Formulation of
HET0016 Decreased Human
Glioblastoma Growth and
Implicated Survival Benefit in Rat
Xenograft Models
Meenu Jain1, Nipuni-Dhanesha H. Gamage2, Meshal Alsulami1, Adarsh Shankar1,
Bhagelu R. Achyut1, Kartik Angara1, Mohammad H. Rashid1, Asm Iskander1, Thaiz F. Borin1,
Zhi Wenbo3, Roxan Ara1, Meser M. Ali2, Iryna Lebedyeva4, Wilson B. Chwang2, Austin Guo5,
Hassan Bagher-Ebadian2 & Ali S. Arbab1
Glioblastoma (GBM) is a hypervascular primary brain tumor with poor prognosis. HET0016 is a selective
CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth. Therefore, to
explore novel treatments, we have generated an improved intravenous (IV) formulation of HET0016
with HPßCD and tested in animal models of human and syngeneic GBM. Administration of a single
IV dose resulted in 7-fold higher levels of HET0016 in plasma and 3.6-fold higher levels in tumor at
60 min than that in IP route. IV treatment with HPßCD-HET0016 decreased tumor growth, and altered
vascular kinetics in early and late treatment groups (p < 0.05). Similar growth inhibition was observed in
syngeneic GL261 GBM (p < 0.05). Survival studies using patient derived xenografts of GBM811, showed
prolonged survival to 26 weeks in animals treated with focal radiation, in combination with HET0016
and TMZ (p < 0.05). We observed reduced expression of markers of cell proliferation (Ki-67), decreased
neovascularization (laminin and αSMA), in addition to inflammation and angiogenesis markers in the
treatment group (p < 0.05). Our results indicate that HPßCD-HET0016 is effective in inhibiting tumor
growth through decreasing proliferation, and neovascularization. Furthermore, HPßCD-HET0016
significantly prolonged survival in PDX GBM811 model.
Glioblastoma (GBM) is a hypervascular malignant tumor with poor prognosis1,2. Because of hypervascularity,
anti-angiogenic therapies (AATs) targeting the vascular endothelial growth factor (VEGF) and VEGF receptor
(VEGFR) axis have been attempted in clinical trials, but the results have not been encouraging3. Moreover, our preclinical studies in a rat model of human GBM also showed resistance to the treatment of receptor tyrosine kinase
inhibitors (RTKIs) and resulted in paradoxical enhancement of neovascularization and tumor growth4,5. Therefore,
we need an agent that will decrease tumor growth and neovascularization with reduced resistance to therapy.
Recently, studies have shown the role of N-hydroxy-N’-(4-butyl-2 methylphenyl) formamidine (HET0016), a
highly selective inhibitor of 20-hydroxy arachidonic acid (20-HETE) synthesis involving enzymes of the CYP4A
and CYP4F families, in inhibiting tumor angiogenesis, proliferation, migration, and regulation of CD133+/
CD34+EPCs6–8. HET0016 was able to inhibit angiogenic responses to several growth factors as well as angiogenesis in gliosarcoma and in the cornea induced by implanted human U251 GBM cells9,10. Our previous study
in breast cancer also showed decreased tumor growth after treatment with HET00168. In previous studies of
GBM, HET0016 was prepared in cremophor and DMSO that was administered either orally or intraperitoneally
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Figure 1. Preparation of HPßCD-HET0016 complex (a) Structure of HET0016 and HPßCD is shown. HPßCD
resembles a shell and it can encase any deliverable drug. To prepare the IV formulation of HET0016, it was first
dissolved in DMSO and added to 30% HPßCD prepared in water. The bucket like structure of HPßCD with
hydrophilic exterior helps encase HET0016 and delivers to the target area. (b) Mass spectrometry of HET0016
in DMSO (left panel), HET0016 complex in plasma (middle panel). HPßCD-HET0016 complex in tissue lysate
(right panel). Plasma and tissue lysate was collected from the rats bearing glioma and injected with single dose
of HPßCD-HET0016 for evaluation of pharmacokinetics.

(IP). However, there was limited success in controlling the glioma due to low bioavailability11. In the present
study, we optimized a condition to make IV formulation of HET0016 with 2-Hydroxypropyl Beta Cyclodextrin
(HPßCD) to improve bioavailability and deliver an effective dose of the drug to the tumor site, especially in the
hypervascular and hypoxic areas of GBM. HPßCD is a derivative of β-cyclodextrin that has been extensively used
as a drug delivery vehicle and recently, FDA has approved the use of HPßCD as a treatment for Niemann Pick
Type C disease12,13. The exploitation of HPßCD as delivery vehicle in GBM may be beneficial due to the porosity
of the tumor vasculature, an enhanced permeability and retention (EPR) effect and reduced off target effects in
the tumor neovasculature14. Moreover, due to smaller size (<1 nm) of the HPßCD encased drug, excess drug can
be cleared rapidly through kidneys. Therefore, we believe that the use of HPßCD as a drug delivery system for
delivering HET0016 in GBM will not have any detrimental effect.
In the current rat xenograft model of GBM, we have performed magnetic resonance imaging (MRI) studies,
which help in analysis of changes in tumor vascular physiology, tumor size, backward transfer constant (kep),
tumor plasma volume (vp), vascular permeability (forward transfer constant, Ktrans), extravascular and extracellular space volume interstitial space volume fraction (ve)15. In addition to MRI, we have also evaluated changes in
histological parameters, effect on survival and signaling pathways following HET0016 treatment. These parameters may allow for a better understanding of the physiological characteristics of the regional tumor environment
and vascularity after HET0016 treatment.
The main purposes of the study are (1) to determine whether HPßCD can be complexed with HET0016 within
reasonable period of time (practical kitchen chemistry) to obtain a water soluble formulation that can be administered intravenously, (2) to investigate the effects of IV administration of HET0016 on human and syngeneic
GBM tumor growth, and survival in patient derived GBM animal models, vascular parameters, histology, and (3)
to identify critical signaling pathways inhibited by HPßCD-HET0016, when administered through IV in the rat
GBM xenograft model.

Results

IV formulation of HET0016 with 30% cyclodextrin. IV formulation of HET0016 using 30% HPβCD
(in solution with water) was stable both at 4 °C and room temperature for an extended time without any precipitation of HET0016 (Fig. 1a shows the structure of HET0016 with cyclodextrin). IV administration of 5-day old
complex solution did not cause any immediate or late detrimental effect on health of the animals. There was no
change in the mass-spectrometric profile between the naked and HPβCD-HET0016 complex alone or mixed with
plasma or cell lysate (Fig. 1b). All profiles showed the molecular weight of HET0016 (complex or naked) between
206 and 207 kDa with retention and elution time of 2.9 minutes.
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Figure 2. Pharmacokinetics of HPßCD-HET0016 in plasma and tissue after IV and IP dose administration
in rat glioblastoma model. The concentrations of HET0016 in plasma or tissue versus time post dose
administration in rat model are shown. Blood samples were obtained for 0–24 hrs after dose administration.
Plasma and tissue HET0016 concentrations were determined by LC-MS/MS after liquid phase extraction. Each
data point is presented as the mean concentration ±SEM (n = 2–4). Concentration of HET0016 in plasma
(a) and tumor tissue (b) after a single HET0016 (10 mg/kg) dose through IV and IP route. Significant values
from t Student test and Mann-Whitney’s test are represented by *p < 0.05 in comparison to IV and IP doses in
the same time point.

HET0016 levels in plasma and tumor tissue.

Rats were orthotopically implanted with U251 cells and
allowed to form the tumor. HET0016 was administered to rats IV and IP as a single dose and sacrificed for pharmacokinetics at different time points. A total of 12 rats were serially euthanized for the measurement of HET0016
levels in plasma and brain tumor tissue at 0, 5, 30, 60, 180 min and 24 h (1440 min) after single IV and IP HET0016
administration (10 mg/kg) (n = 2–4 per time point) and analyzed by LC-MS/MS as described in pharmacokinetics section in material and methods. The level of HET0016 was 7-fold higher in plasma in the group of IV route at
5 min and 60 min time point (105042 and 36880.18 ng/ml) as compared to the IP group (15938.1 and 4773.0 ng/
ml) (p < 0.005) (Fig. 2a). The plasma concentration suggests there was rapid elimination of HET0016 with a
half-life of approximately 45 min for both the IV and IP groups. The concentration of HET0016 in tumor tissue in
the IV group was much higher than that of the IP group at 60 min (9251 ng/g vs 325 ng/g) and 24 h (42.7 ng/g vs
7.4 ng/g) (p < 0.01) (Fig. 2b). There was no significant difference at middle time point at 180 min.

Effect of HET0016 on tumor growth and vascular parameters. Rats were orthotopically implanted
with U251 cells and allowed to form tumor for 8 days. After day 8, animals were treated with HET0016 and followed up for 21 days. A detailed schema of treatment schedule is shown in Fig. 3. Treatments on the same day and
seven-day waiting period were chosen to mimic the post-surgical cases and post diagnosis of GBM, respectively,
as described previously4. Tumor growth was measured by in vivo MRI. IV administration of HET0016 significantly reduced the tumor growth (in delayed [day 8–21] treatment) compared to that of vehicle treated animals
(p < 0.001) (Fig. 4a) and there was reduced growth with early (day 0–21) treatment although significant difference
was not achieved. When compared to the IP administered treatment, tumor growth was reduced only with early
IP treatment, although significant difference was not achieved (Fig. 4a). However, when all groups were compared, significant (p < 0.005) reduction of tumor volume was found for delayed IV treatment group compared to
the vehicle and delayed IP HET0016 treated groups (Fig. 4a).
Vascular parameters were evaluated to gain information about the vascular kinetics of the tumor environment.
Delayed IV HET0016-treated animals showed significantly increased blood flow, which may indicate normalization of blood vessels causing enhanced flow although there was no significant difference in blood flow (rCBF)
among the IP and early IV treated groups (Fig. 4b). As expected, late IP or IV HET0016 treated animals showed
significantly lower vp (blood plasma pool), ve (extracellular space or interistial volume), Ktrans (forward permeaScientific Reports | 7:41809 | DOI: 10.1038/srep41809
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Figure 3. Schematic representation of treatment schedule. U251 glioma cells were implanted orthotopically
in rat’s brain and treated with HPßCD-HET0016 as described in material and methods.

bility transfer constant) compared to that of corresponding vehicle treated groups (p < 0.01) (Figs 4c and 5a–c).
Both early IP and early IV groups also showed significantly lower vp compared to that of corresponding vehicle
treated groups (Fig. 4c). As rCBF analysis showed higher blood flow (Fig. 4b), it is expected that normalized vessels will have less Ktrans (Fig. 5a) compared to that of neovessels. Therefore, the blood plasma pool (vp) would be
reduced in tumors with normalized vessels (Fig. 4c). When the extravascular extracellular space volume (ve) was
compared, both early and delayed IV HET0016- treated groups showed significantly decreased ve compared to
that of vehicle and IP-treated groups (Fig. 5c). There was no difference in kep (backflow transfer) between the IP
and IV group of animals (Fig. 5b). We also evaluated the blood chemistry to determine the toxicity following 0–21
days of treatment with either vehicle, IV formulated or IP HET0016 in GBM xenografts. We did not observe significant changes on liver function, renal function, important enzymes, pancreas, and lipid profile after HET0016
treatment in IP and IV groups (Supplementary Table 1).

Proliferation (Ki67), Micro Vessel Density (MVD), Smooth muscle Actin (αSMA), extracellular
and extravascular space (EES). Brains were removed from the rats (U251 xenograft model) following

euthanasia and prepared for immunohistochemistry as described in material and methods. Tumor section in the
early and delayed IV or IP treatment and vehicle groups were stained for Ki67, which is a marker of cellular proliferation. Ki67 positive and negative tumor cells were counted within the tumor areas. Ki67 positive cells along the
endothelial lining were omitted during counting and calculation of the proliferative cells. In IP treatment groups,
only delayed treatment showed reduced proliferation but not significant (Fig. 6a,c). However, in IV treatment
groups, significant decreased proliferation was observed in both the early and late treatment groups as compared
to corresponding vehicle groups (Fig. 6b–d).
Tumor tissues were also stained for laminin to analyze for microvessel density (MVD). Laminin, a basement
membrane glycoprotein, is found under the endothelium, encasing the pericytes and smooth muscle cells in the
vessel wall and has been shown to be an excellent marker for blood vessels in the brain. Tumor sections were
stained with laminin antibody and images from the positive area were taken at 10x and 20x and counted for
a number of vessels. We found no significant difference in expression of laminin among the IP-treated groups
(Fig. 7a–c, top left panel). However, there was significant reduced expression of laminin with lower number of
vessels (3–50 fold less) in the IV treatment group especially around the rim of tumor as compared to vehicle
(p < 0.01) (Fig. 7d–f top right panel). We also performed αSMA immunostaining to demonstrate the effect on
vessels in pericyte area around tumor periphery and found there was a significantly smaller number of vessels with reduced expression of αSMA in the IV treatment group as compared to vehicle (p <  0.02) (Fig. 7e,f).
However, no such differences were detected in the early and delayed IP-treatment groups (Fig. 7b,c).
Differences in the area of extracellular and extravascular space were also analyzed by using H&E stained
images from the IP and IV groups using the color thresholding method as described earlier5. There was no difference observed among IP treatment groups as compared to vehicle (Supplementary Figure 2a,b top panel).
However, we found a threefold reduction in the extracellular and extravascular space in the IV-treated groups
(both early and delayed) as compared to vehicle (p < 0.01) (Supplementary Figure 2c,d bottom panel).

Reduced expression of cell proliferation, inflammatory and angiogenic proteins were detected
in glioma treated with HET0016. A protein array was performed using tissue lysates for angiogenic

related growth factors using a membrane based protein array kit. Supplementary Figure 3 shows the expression of important proteins related to angiogenesis among the control, early and delayed IV treatment groups.
Pro-angiogenic proteins such as VE-cadherin (vascular endothelial cadherin-vasculogenesis), bFGF (basic
fibrobalst growth factor), IL-8 (chemokine CXCL8) and MCP-1 (a CCL2 ligand) were significantly downregulated in the delayed IV treatment group while expression of anti-angiogenic proteins such as Tie-2, angiostatin
and angiopoietin-2 was increased in the delayed treatment group (day 8–21; Supplementary Figure 3a) as compared to control (p < 0.03). In the early treatment group, expression of proteins, such as MCP-1, angiostatin
and angiopoietin-2 followed a similar trend, indicating a significant effect of the treatment, particularly on the
factors secreted or expressed by endothelial and inflammatory cells. Western blot was performed to determine
the expression of proteins related to cellular proliferation (p-ERK), survival (p-AKT), inflammation (COX-1/2),
arachidonic acid metabolism (CYP4A11), signal transducers and activators of transcription (p-STAT1). We also
Scientific Reports | 7:41809 | DOI: 10.1038/srep41809
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Figure 4. HPßCD-HET0016 reduces tumor growth and vascular parameters in rat glioblastoma model.
(a) Representative post contrast T1-weighted images from in vivo imaging of rat with glioma show tumor size
from different groups of animals. Semi-quantitative analysis shows significantly reduced tumor volume in
animals that received HET0016 from day 8 and continued for 2 weeks (n = 5 to 8). (b) Relative cerebral blood
flow maps created from arterial spin labeling techniques. Semi-quantitative analysis (bar graphs) indicates
higher flow in IV HET0016-treated groups (started on day 8) compared to that of vehicle-treated group
(n = 5 to 8). (c) Tumor plasma volume maps and semi quantitative analysis are shown. Both IV and IP
treatment with HET0016 caused a significant decrease in tumor plasma volume (vp) compared to vehicle and
corresponding IP-treated groups. Each group is represented as the mean of the total measurable MRI sections
from animals of each group (n = 5–8 animals but 7–16 sections). Significant values from ANOVA test followed
by Fisher’s exact test are represented by *p < 0.05 compared to the corresponding vehicle group. An outlier data
point (from a single MRI section) was removed as described in our material and methods.
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Figure 5. HPßCD-HET0016 influences vascular parameters in rat glioblastoma model. MRI images from
in vivo rat imaging show significant changes in vessel permeability (Ktrans) (a), and ve (interstitial space volume)
(C) but no changes in kep (backflow rate constant) (b) in early and delayed treatment in IV groups. Significant
values from ANOVA test followed by Fisher’s exact test are represented by * and #p < 0.05 compared to (*)
vehicle 8–21 vs IV HET 8–21 and vehicle 0–21 vs IV HET 0–21, and (#) IP HET 8–21 vs IV HET 8–21 and IP
HET 0–21 vs IV HET 0–21. Each group is represented as the mean of the total measurable MRI sections from
animals of each group (n = 5–8 animals but 7–16 sections), analyzed by MRI at 0.5 μm thickness in a range up to
7–16 viewed slices of each animal.
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Figure 6. HPßCD-HET0016 treatment results in reduced proliferation, migration in rat glioblastoma
model. (a,b) Ki-67 immunohistochemical staining was done as a marker of proliferation in tumor tissues.
Rats treated with HET0016 starting on day 8 showed significantly fewer proliferative cells in the tumor in the
IV group compared to the IP group. (c,d) Bar graphs represent the proportion of Ki67 positive tumor cells
compared to total number of tumor cells in tumor area of each group. Images were taken in 40x magnification.
The brown nuclei color shows the positive labelling cells. Statistically significant differences were verified by
ANOVA followed by Bonferroni’s test. *p < 0.05 in comparison to the respective vehicle group.
determined the expression of, HIF-1α, EGFR, VEGF, MMP-2 (angiogenesis) and p-NFKB (inflammation), to
investigate the effects of IV administered HET0016 on the rat model of GBM. We observed reduced levels of
COX-1, CYP4A11, p-ERK, p-AKT, p-STAT1, HIF1α, EGFR, VEGF, MMP-2 and p-NFKB proteins in tumors
obtained from both IV treatment groups as compared to vehicle (Supplementary Figure 3b), which confirms the
influence of HPβCD-HET0016 on cell proliferation, migration, and inflammation pathways.

Effect of HET0016 on survival in GBM811 and HF2303.

We evaluated the effect of HET0016, TMZ
alone or in combination with radiation on survival in PDX derived tumor model of GBM811 and HF2303. First,
we tested the effect of treatment in vitro 3D culture model (HF2303) and found that the treatment with HET0016
or TMZ alone or combination showed the inhibition of the growth of neurospheres Fig. 8a). Similar studies were
planned in vivo model and we observed that HET0016 treatment alone or in combination with TMZ in irradiated
tumor bearing animals resulted in reduced tumor growth and prolonged survival in both GBM811 (p <  0.004)
and HF2303 PDX models (p = 0.18) (Fig. 8b). The overall survival in GBM811 model was prolonged to 26 weeks
after the treatment with HET0016 plus TMZ and radiation, while control animals (supercontrol and irradiated
only control) survived only for 10 weeks similar to the clinical setting (Fig. 8c). The cumulative survival was 100%
for HET0016 plus TMZ combination group as compared to 66% for TMZ alone, 33% for HET0016 alone at 26
weeks until the end of the study without demonstrating any evidence of recurrence (Table in Fig. 8d). Therefore,
the current study provides evidence that combination therapy (HET0016 + TMZ) with irradiation can improve
survival in GBM. In the second PDX model of HF2303, the HET0016 treatment alone and in combination with
TMZ, resulted in reduced tumor volume and prolonged survival of 26 weeks vs. only 17 weeks of irradiated control (p < 0.10). The cumulative survival was 25% for both HET0016 plus TMZ combination group and HET0016
alone group at 26 weeks as compared to 0% in radiation only group (p < 0.18). Thus, data indicates combination
treatment with HET0016 plus TMZ and irradiation resulted in better survival benefit as compared to radiation
alone. Overall, the response was better in GBM811 model than HF2303 model and may be attributed to difference
in growth and genetic characteristics. We also measured the presence of 20-HETE and MGMT in different glioma
cells (GL261, U251, HF2303 and GBM811) and GBM811 showed comparatively lower amount of 20-HETE and
methylguanine DNA methyltransferase (MGMT) levels (Supplementary Figure 5 and 6), which may indicate
better treatment results following HET0016, radiation and TMZ in GBM811 PDX model16,17.
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Figure 7. HPßCD-HET0016 treatment results in reduced neovascularization in rat glioblastoma
model. Laminin and αSMA immunohistochemistry staining was done in tumor tissues to determine the
neovascularization (a,b,d and e) Representative images from brain tumor tissues are shown at 10x and 20x
from the IP (left panel) and IV (right panel) groups. Red arrows indicate blood vessels. Four areas on the tissue
section were selected and the number of vessels counted. (c and f) Laminin and αSMA quanfication. Each
bar represents an average of four areas and was estimated in multiple samples from each group (n =  2–4).
Significant difference is indicated by *p < 0.05 compared to the respective vehicle group.

Effect of IV HET0016 on GL261 syngeneic GBM. We also assessed the effect of IV HET0016 on tumor
growth in syngeneic model of GBM using GL261 cell line. All animals underwent MRI and tumor volume
was measured from the MRI images. There was significantly reduced tumor volume in animals treated with
IV HET0016 (54.33 ± 12.37 mm3) compared to that of vehicle treated animals (131.70 ± 19.45 mm3) (p <  0.007)
(Supplementary Figure 1).

Discussion

Despite the availability of current chemotherapy and targeted therapies in GBM (e.g. temozolomide and bevacizumab), not many therapeutic benefits have been achieved due to target developing drug resistance18. Most therapies have produced a decrease in tumor growth during early stages of treatment followed by aggressive tumor
recurrence. Mu et al. previously developed water-soluble IV formulation of HET0016 which rapidly penetrated in
the rat normal brain and inhibited the formation of 20-HETE after cerebral ischemia19. Here, we have developed
an improved IV formulation of HPßCD-HET0016 that dissolves in 2–3 min compared to the 48 hrs as reported
by Mu et al. IV administration of HPßCD-HET0016 in a rat model of human GBM significantly reduced tumor
growth in developing or developed tumors as compared to IP HET0016 treatment. It appears that the IV formulation facilitated increased delivery of HET0016 to the hypervascular and hypoxic tumor sites, due to EPR effects.
Moreover, the effect of IV HET0016 was not cell specific and showed similar reduced tumor growth in syngeneic
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Figure 8. Treatment with HET0016 and TMZ prolongs survival in PDX models. (a) Treatment with
HET0016 and TMZ inhibit neurospheres growth in vitro: HF2303 was treated with HET0016 and TMZ alone
(100 μM), in combination with TMZ and followed up for 14 days. (b) HF2303 and (c) GBM811 show the
effect of HET0016 and TMZ on survival rate of the mice in groups 1, 2, 3, 4 and 5 of treatment schedules (as
described in Material and Methods) were evaluated from the first day of treatment until death. X-axis represents
cumulative survival time in weeks. Table in Fig. 8d summarize the details of duration in weeks and % survival.
Athymic nude rats were implanted orthotopic with HF2303 and GBM811. Six to ten weeks after implantation,
rats were randomized into five treatment groups receiving PBS, radiation, HET0016, TMZ, HET0016 plus TMZ
for another 6 wks, as described in Materials and Methods. #The animals were not included due to the technical
difficulty. Significant difference is indicated by *p < 0.05 vs irradiation and super-control, $p-value was 0.18 vs
irradiation control, achieved by Kaplan Meier analysis and Log-rank test.
tumor (GL261) models. The distribution profile of HPßCD-HET0016 formulation showed better bioavailability
and retention in tissue with a higher brain to plasma ratio in the IV treatment group as compared to the treatment
with IP preparation. The findings suggest that the IV formulation or encapsulation of HET0016 in a non-toxic
delivery system may have the benefits of increased half-life (protect the drug from degradation during circulation
and early clearance), lower toxicity, enhanced EPR effect over the IP preparation and improved the therapeutic
index14. Furthermore, enhanced accumulation of macromolecular drugs in tumor tissues can occur as compared
to normal tissue due to impaired lymphatic drainage and porous blood vessels in GBM with abnormal molecular and fluid transport dynamics20,21. The effect of enhanced delivery of IV HET0016 is supported by vascular
parametric analysis in MRI studies. Vascular parametric analysis supported the effect of the drugs, where the IV
formulation decreased vascular permeability (Ktrans), tumor blood volume (vp), and extracellular extravascular or
interstitial space volume (ve) but increased the blood flow to the delayed treated tumors in GBM.
TMZ is widely used alkylating agent for the treatment of primary as well as recurrent GBM. Effect of TMZ
requires functional DNA mismatch repair (MMR), low levels of methylguanine DNA methyltransferase (MGMT)
and DNA repair genes16,22,23. Unfortunately, majority of the primary and recurrent GBMs have unmethylated
or active high level of MGMT, which make TMZ treatment unresponsive17,24,25. We evaluated the synergistic
effect of HET0016 alone or in combination with TMZ on the survival of animals treated with 30 Gy irradiation
in patient-derived xenograft models (PDX) (GBM811, HF2303) (treatment schedule shown in Supplementary
scheme). After Administration of HET0016 alone and in combination with TMZ and radiation in GBM811 and
HF2303 models for 6 weeks resulted in good response and tumor did not relapse until 6 months (endpoint of
the study). Therefore, HET0016 plus TMZ combination may prolong survival and reduce therapy resistance. The
synergistic effect may be due to the role of HET0016 in sensitizing the action of TMZ and irradiation by reducing
DNA repair mechanisms. Our preliminary study indicated that HET0016 administration resulted in down regulation of DNA repair genes (unpublished preliminary data, Supplementary Fig. 4). The continuous exposure of
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cellular DNA to potentially harmful environmental and internal insults necessitates redundant and overlapping
DNA repair mechanisms26. Therefore, successful destruction of GBM tumors may require a combined approach
utilizing standard treatments in combination with inhibition of DNA repair pathways.
The anti-tumor effect of HPßCD-HET0016 was supported by decreased tumor cell proliferation, migration,
and neovascularization. There was a clear reduction in the number of Ki67 + cells in the IV treatment groups as
compared to IP groups. The reason for observing the significant reduced proliferation in IV treatment groups
may be that HET0016 is effective in preventing the regrowth of established tumor due to increased bioavailability
following IV administration. We also believe established tumor has developed-neovascularization and leaky vessels, which allow EPR effect to be more pronounced in groups treated with IV formulated HET0016. In addition,
we suggest that the effect of HET0016 on tumor growth may be attributed to the reduced basic fibroblast growth
factor expression (bFGF or FGF-2) after early and delayed treatment. bFGF is a potent mitogen that maintains
cancer cell stemness and leads to drug resistance by enhancing the blood-brain-barrier function of endothelial
cells27,28. These results are supported by an earlier study of Guo et al.29 which showed chronic in vivo administration of HET0016 (IP, 10 mg/kg/day) reduced the volume of 9 L gliosarcoma, accompanied by mitotic and
vascularization reduction.
GBM tumor vessels are tortuous, disorganized, highly permeable, decreased pericyte coverage and a solid
basement membrane structure30,31. We found overall fewer vessels in both early and delayed IV treatment group,
with reduced EES, laminin, and αSMA staining, especially at the invasive margin of the tumor indicating the role
of HET0016 in inhibiting the growth of new blood vessels. These observations were supported by a published
report that suggested that the pericyte line around new endothelial cells sprouts from tumor vessels, play a role
in blood vessel growth, and is suggested to be a potential target in AAT therapy32. In addition, this is further
supported by a high expression of angiopoietin-2, Tie-2 molecules and reduced VE-cadherin expression, which
is associated with pericyte endothelium suggesting an effect of HET0016 on vascular development and stability33. We suggest that HPßCD-HET0016 has a primary effect on blood vessels, which by normalization increased
the bioavailability of drug to the hypoxic tumor sites. MRI vascular parametric analysis also correlates with
immunohistochemistry; especially the normalization of vessels in the IV delayed treatment groups that resulted
in decreased permeability (Ktrans) and overall reduced plasma volume fraction (vp). The treatment also caused
decreased EES volume indicated by decreased ve, which is also validated in H&E histological analysis. Similarly,
Guo et al also showed normalization of vessels in 9 L tumor following HET0016 treatment10.
In our study, we observed that HET0016 reduced expression of the pro-angiogenic proteins but increased the
expression of anti-angiogenic proteins expression to achieve equilibrium to reduce tumor growth. Expression
of pro-angiogenic factors such as IL-8, MCP-1, VEGF and SDF-1αwere decreased, while expression of inhibitors of the angiogenic process such as angiostatin, angiopoietin-2/Tie-1, and Tie-2 proteins were increased after
HET0016 treatment. Recently, a study in triple negative breast cancer showed a similar effect of IP HET0016 on
pro-angiogenic factors8. We observed that HPßCD-HET0016 reduced IL-8 expression. IL-8 has recently been
shown to be a critical factor in regulating cancer cell stemness and invasion, and higher expression was associated
with poor survival and therapy resistance in glioma34. Moreover, HET0016 treatment reduces the expression of
MCP-1 and SDF-1α, key chemokines responsible for trafficking and activation of monocytes/macrophages and
have been involved in inflammation and angiogenesis35. MCP-1-induced angiogenesis has been reported to be
mediated through up-regulation of HIF-1αand subsequent activation of VEGF35. Therefore, HPßCD-HET0016
may be acting as an inhibitor of inflammation and angiogenesis growth responses in GBM tumor cells through
regulating HIF-1αand VEGF. Interestingly, there were less hypoxic areas in HPßCD-HET0016-treated tumors as
shown by reduced HIF-1αprotein expression. Reduced HIF-1αexpression also resulted in low VEGF expression
after HPßCD-HET0016 treatment. VEGF signaling and angiogenesis and highly affected by HIF-1αlevels and
regulates endothelial cell proliferation, migration, and permeability of blood vessels. Studies have shown high
expression is correlated with increased metastases, vasculature, and tumor recurrence28. These findings suggest
that HPßCD-HET0016 regulated the expression of pro-and anti-angiogenic factors to achieve the balance in the
maintenance of the tumor microenvironment8.
In the current study, we studied effect of HPßCD-HET0016 treatment in the arachidonic acid metabolism
pathway. Previously, HET0016 has been shown to have an effect on expression of CYP4A enzymes. In present
study, we found HET0016 was able to reduce the protein expression of CYP4A11 and COX-1, thereby influencing
inflammation, angiogenesis, and MAPK signaling in GBM36,37. Previous studies have also documented a similar
role of HET0016 in glioma, gliosarcoma, lung, and breast cancers10,29,38. A study in colon cancer suggested combination therapy of rofecoxib and HET0016 might be a new treatment that can improve the anti-tumor efficacy of
rofecoxib alone39. In addition, we also investigated role of p-NFκB as marker of inflammation and proliferation.
Previous studies have shown a pro-survival role for p-NFκB in glioma and an association with chemo resistance40.
We demonstrated reduced levels of p-NFκB after HET0016 treatment suggesting an anti-proliferative effect in
glioma.
Previous study have shown that GBM has frequent overexpression of EGFR, which leads to activation of
the P13/Akt pathway, associated with adverse clinical outcome and has been suggested to be a therapeutic target41–43. We showed that HPßCD-HET0016 repressed the expression of EGFR, ERK, and Akt, a target of MEK.
We also determined expression of p-STAT1, a tumor suppressor protein involved in the p38/MAPK pathway in
response to IFN-αand stress. Higher expression of p-STAT1 was shown to be associated with poor prognosis
in glioma and depletion of IRF1/STAT1 signaling has been reported to increase the efficacy of anti-VEGF (bevacizumab) therapy in a glioma xenograft model44–46. We found that HPßCD-HET0016 treatment also reduced
the levels of pSTAT1, indicating HET0016 can improve overall prognosis in glioma. In summary, we have established a highly soluble HPßCD-HET0016 complex for IV administration that reduced GBM growth, normalized vasculatures, decreased permeability, and EES volume both in established and growing tumors through
enhanced bioavailability compared to conventional IP HET0016 preparation. Our results showed that HET0016
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Figure 9. Summary and hypothetical model. Tumors consist of an abnormal vasculature, composed mainly
of immature vessels with increased permeability. The less densely packed cells allow drugs or complexes
to accumulate in tumor tissue. Treatment with HPßCD-HET0016 leads to reduced expression of αSMA
and increased expression of angiopoietin-2 and Tie-2, which may lead to reduced tumor vasculature that is
inadequate to support tumor growth and may lead to tumor dormancy. Our results suggest that HET0016
reduces cancer cell growth, invasion, and vasculature by reducing the expression of signaling molecules in the
MAPK, PI3K/AKT, and inflammation pathways.

in combination with TMZ and radiation enhanced the anti-tumor efficacy and prolonged survival in GBM xenograft models as compared to TMZ alone. Anti-tumor properties of HPßCD-HET0016 resulted in decreasing
proliferation, hypoxia, migration, stemness, and vasculatures in glioma by altering the balance of pro-angiogenic
and anti-angiogenic balance, PI3K/Akt, p38/MAPK and inflammation pathways (Summary model in Fig. 9).
Therefore, HPßCD-HET0016 could be tested in clinics to explore combination therapies with TMZ or radiotherapy for GBM.

Materials and Methods
Ethics statement.

Animal experiments were performed according to the NIH guidelines and the experimental protocol was approved by the Institutional Animal Care and Use Committee of Henry Ford Health System
and Augusta University (formerly Georgia Regents University) (Approval number: 2014–0625). All animals were
kept under pathogen-free conditions at room temperature (21 to 25 °C) with exposure to light for 12 hours and
12 hours in the dark. Food and water were offered ad libitum. Body weight was measured twice weekly as an
indicator of overall animal health. All surgeries were performed under ketamine - xylazine anesthesia, and efforts
were made to minimize suffering. Euthanasia for the moribund animals was performed in a CO2 chamber.

Chemicals. HPßCD (2-hydroxy Propyl-β-Cyclodextrin) was purchased from Sigma-Aldrich (St. Louis, MO),
cell culture media was from Thermo Scientific (Waltham, MA), and fetal bovine serum was purchased from
Hyclone (Logan, Utah). HET0016 was obtained from Dr. JR Falck of UT Southwestern University, Texas, and
also synthesized by Dr. Iryna Lebedyeva in the department of Chemistry and Physics, Augusta University with a
purity of more than 97%. Cell culture grade DMSO was purchased from Fischer Scientific (PA). Blood chemistry
profiles and electrolytes were determined Using third party vendor (Antech Diagnostic).
Tumor cells. Human glioma U251 cell line was obtained from Dr. Steve Brown of Henry Ford Health System.
The cell line was authenticated in July 2014 using the STR profiling method. GL261 syngeneic (C57BL/6 mouse
derived) GBM cell line was obtained from Dr. Ted Johnson (Augusta University) and was authenticated in 2016.
The cell line, U251 was grown in high glucose (4.5 g/L) Dulbecco’s modified eagles medium (DMEM) and GL261
in RPMI (Roswell Park Memorial Institute) (Thermo Scientific), supplemented with 10% fetal bovine serum
(FBS), 2 mM glutamine and 100 U/ml penicillin and streptomycin at 5% CO2 at 37 °C in a humidified incubator.
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Patient derived GBM cells (HF2303) was obtained from Dr. Tom Mikkelsen’ s lab at Henry Ford Hospital and
was grown in neurosphere medium (NM), composed of DMEM/F-12 supplemented with N2 (Gibco), 0.5 mg/ml
BSA (Sigma), 25 μg/ml gentamicin (Gibco), 0.5% antibiotic/antimycotic (Invitrogen), 20 ng/ml basic fibroblast
growth factor, and 20 ng/ml EGF (Peprotech). Cells were maintained in culture for up to passage 10 (low passage).
Patient derived PDX GBM cells, GBM811 was obtained from North Western University and was propagated in
immunocompromised NOD-SCID mouse and tumor was disintegrated into cell suspension at the time of tumor
implantation in nude rats.

Intraperitoneal (IP) formulation of HET0016.

For IP formulation, 2 mg of HET0016 was dissolved in
1 ml of solution containing 80% PBS, 10% of dimethyl sulfoxide (DMSO) (Sigma, St. Louise, MO, USA) and 10%
cremophor (Sigma, St. Louise, MO, USA). The mixture was vortexed and sonicated until HET0016 was dissolved.
Each rat received 10 mg/kg/day dose and the dose has been used according to previous publications10,11.

Intravenous (IV) formulation of HET0016 using HPßCD (2-hydroxy Propyl-B-Cyclodextrin).

Previous published methods have used 48 hours incubation with continuous rotation to make a complex of
HET0016 with HPßCD for the IV formulation19. Here, we describe a rapid and safe method to synthesize IV formulation of HET0016 without using a sonicated water bath or long rotation. HPßCD has a bucket-like structure
with hydrophilic outer shell but hydrophobic inner cavity (Fig. 1a). However, optimized conditions are needed
to insert the drug into the HPßCD cage since HET0016 is a heat sensitive compound and can be degraded with
long-term rotation at room temperature. HET0016 was dissolved in DMSO (2 mg/50 μl) and was added slowly
to a 30% HPßCD solution in sterile water (950 μl) with continuous vortex, and the turbid solution became clear
within 2–3 minutes. The final concentration of DMSO was 5%. We have tested mass-spectrometric profiles of
HET0016 complexed with HPßCD as well as HET0016 dissolved in DMSO (Fig. 1b). The solution of HET0016
in DMSO showed a peak at 2.9 min retention elution time, and it did not change when HET0016 was complexed
or encapsulated with HPßCD.

HET0016 pharmacokinetics in plasma and tissue lysate.

Twelve nude rats (RNU nu/nu) obtained
from Charles River Laboratory (Frederick, MD) were used for pharmacokinetics studies. A single IV injection of
HET0016 or vehicle (10 mg/kg) in 30% cyclodextrin or IP injection of HET0016 was administered to the animals
in the respective groups. Animals were euthanized at multiple time points, and brain tumor tissue was collected
(60, 180 min, 24 hrs). The details are provided in Supplementary methods.

Animal model and treatment schedules. Forty-eight nude rats (RNU nu/nu) weighing 140–150 grams
obtained from Charles River Laboratory (Frederick, MD) were used in these experiments. Human glioma U251
cells (400 k in 5 μL), were implanted orthotopically at 3 mm to the right and 1 mm anterior to bregma according to
published methods47. Following implantation, animals received treatment of HPßCD-HET0016 (IV, 10 mg/kg per
day); an equivalent dose of IV HPßCD alone as a vehicle; HET0016 (IP, 10 mgkg/day), or an equivalent dose of IP
vehicle alone for either two or three weeks. The details of animal model are described in Supplementary methods.
In vivo MRI and measurement of vascular kinetics. All animals underwent MRI, vascular kinetic,
and tumor volume analyses as described previously on day 225 as depicted in Fig. 3. The details on methods are
provided in Supplementary methods section.
Tumor volume analysis. Post contrast T1-weighted images were used to determine the tumor volume. At
least two investigators, blinded to the various treatment groups, determined the volume by drawing irregular
region of interest (ROIs) for all slices containing tumor. To calculate the exact volume, investigators summed up
the number of slices and multiplied by the slice thickness.
Survival studies in PDX GBM models. Anti-tumor effects and survival studies were conducted in patient
derived xenograft GBM model (PDX) using HET0016 as an adjuvant to the current treatment strategies of GBM
(radiation and TMZ). Two different PDX models were developed using HF2303 (n = 11) and GBM811 (n =  13).
Cells were suspended in PBS and 2 ×  105 cells in 5 μl were injected orthotopically into brain of each, 5–7-week-old
nude rats, as described previously47–50. Prior to the start of treatment, animals underwent MRI at 6 weeks for
GBM811 and 10 weeks for HF2303 before the start of treatment to confirm the presence of a 3 mm3 tumor.
Thereafter, animals were randomly assigned to five treatment groups and details of the treatment are shown
in Supplementary scheme. The five groups of treatment in the present study were as follows: (1) supercontrol;
tumor bearing animals were treated with PBS (IV) twice weekly. (2) Irradiation control; tumor bearing animals
received a single dose of 30 Gy radiation encompassing the tumor. (3) Irradiation +  HET0016; following single
dose of 30 Gy irradiation tumor bearing animals received IV HET0016 (10 mg/kg, 5 days/week, every other week
for 6 weeks. (4) Irradiation + TMZ; following single dose of 30 Gy irradiation tumor bearing animals received
oral TMZ (50 mg/kg, 2 days/week every other week for 6 weeks). (5) Irradiation +  HET0016 +  TMZ; following single dose of 30 Gy irradiation tumor bearing animals received IV HET0016 plus oral TMZ for six weeks.
HET0016 was given on 1st, 3rd and 5th weeks and TMZ was given on 2nd 4th and 6th week following irradiation. All
animals (GBM 811 and HF2303) received 30 Gy of irradiation in a single fraction before the treatment of TMZ
and HET0016 alone or in combination except the super-control group that did not go through irradiation or any
other treatments. A single dose of 30 Gy radiation was given in an area encompassing the tumor using an X-ray
based image-guided micro small animal radiation research platform from Gulmay Medical Inc. (SARRPTM, an
Xstrahl company). All surviving animals underwent 2nd set of MRI following 6 weeks of treatments to determine
the effects on the tumor volume. 3rd set of MRI was obtained from all surviving animals 4–6 weeks after the end
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of the treatment. 4th set of MRI was also obtained from all surviving animals at the end of the studies (26 weeks
following tumor implantation). All animals were checked for weight gain or loss at least 2 times a week from the
day of tumor implantation. Any sign of morbidity was also noted. Survival was calculated from the day of tumor
implantation until death. One hundred and eighty-three days after tumor implantation, the experiment was terminated, and the surviving animals were sacrificed. All rats were autopsied at death to examine the antitumor
efficacy of each treatment regimen. Our previous experience showed that HF2303 GBM bearing animals die by
16–20 weeks and GBM811 tumor bearing animals die in 12–16 weeks if not treated.

Histopathology.

Tissues were stained for proliferation (anti-Ki 67 antibody, Millipore, USA), human specific MHC-1 marker (anti-MHC-1 antibody, now HLA-A, Abcam), anti-laminin antibody (for blood vessels), and
smooth muscle actin (SMA) for pericytes (anti-αSMA antibody abcam, USA) using standard immunohistochemical procedure as described previously and included in Supplementary methods 8.

Statistical analysis. Comparison between drug and vehicle-treated groups was done by using Student’s
t-test. When more than two groups were analyzed, we used ANOVA followed by Bonferroni test for normal
distribution or Fisher’s exact test. All data were expressed as means ±  SEM. P value of <0.05 was considered significant value in all tests. The criteria to exclude an outlier were the value outside of the range of mean ±  twice the
standard deviation (if necessary). Body weight, tumor volume, and survival were compared among PBS-treated,
HET0016-treated, TMZ-treated, and HET0016 plus TMZ–treated groups. Kaplan Meier analysis was performed
to determine the survival of the animals bearing PDX derived GBM and log rank was used to compare the survival between the two groups.
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